Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metabolic Effects of KHK Inhibition in NAFLD
NCT05463575Phase 2Completed
- Sponsor
- Maastricht University Medical Center+
- Start
- Oct 2022
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of PF-06835919 in non-alcoholic fatty liver disease (NAFLD), sponsored by Maastricht University Medical Center+. Started Oct 2022; status: completed.
02
Drugs
PF-06835919
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT05463575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05463575.